Description |
lipoprotein(a) |
chymotrypsin like elastase 1 |
Image |
No pdb structure |
No pdb structure |
Cellular Component |
|
|
Molecular Function |
|
|
Biological Process |
|
|
Pathways |
|
|
Drugs |
|
- N,N-dimethylformamide
- Cumidine
- Mdl 101,146
- 2-[5-Methanesulfonylamino-2-(4-Aminophenyl)-6-Oxo-1,6-Dihydro-1-Pyrimidinyl]-N-(3,3,3-Trifluoro-1-Isopropyl-2-Oxopropyl)Acetamide
- N-{4-[(Carboxymethyl)carbamoyl]benzoyl}-L-valyl-N-[(3S)-1,1,1-trifluoro-4-methyl-2-oxo-3-pentanyl]-L-prolinamide
- N-{[(2-Methyl-2-propanyl)oxy]carbonyl}-L-alanyl-L-alaninamide
- N-[2-(1-Formyl-2-Methyl-Propyl)-1-(4-Piperidin-1-Yl-but-2-Enoyl)-Pyrrolidin-3-Yl]-Methanesulfonamide
- Freselestat
- (3R)-3-ethyl-N-[(4-methylphenyl)sulfonyl]-L-aspartic acid
- (TERT-BUTYLOXYCARBONYL)-ALANYL-AMINO ETHYL-FORMAMIDE
- (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE
- [1-(3-CHLORO-2-FORMYL-PHENYLCARBAMOYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER
- METHYL(2-ACETOXY-2-(2-CARBOXY-4-AMINO-PHENYL))ACETATE
- (2R)-3-{[(BENZYLAMINO)CARBONYL]AMINO}-2-HYDROXYPROPANOIC ACID
- 3-[[(METHYLAMINO)SULFONYL]AMINO]-2-OXO-6-PHENYL-N-[3,3,3-TRIFLUORO-1-(1-METHYLETHYL)-2-OXOPHENYL]-1(2H)-PYRIDINE ACETAMIDE
- (2S,3S)-3-FORMYL-2-({[(4-METHYLPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID
- (2S,3S)-3-FORMYL-2-({[(4-NITROPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID
|
Diseases |
|
|
GWAS |
- Aortic valve stenosis ( 29511194)
- Aortic-valve calcification ( 23388002)
- Apolipoprotein A1 levels ( 32203549)
- Apolipoprotein B levels ( 32203549)
- Blood protein levels ( 28240269)
- Body mass index ( 26426971)
- Body mass index (age>50) ( 26426971)
- Body mass index x sex x age interaction (4df test) ( 26426971)
- Calcific aortic valve stenosis ( 32141789)
- Cholesterol, total ( 24097068 28270201 25961943 20686565)
- Coronary artery disease ( 32469254 29212778 24262325 30104761 26343387 28714974 33020668)
- Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) ( 28714975)
- Coronary artery disease in diabetes ( 30003307)
- Coronary artery disease or ischemic stroke ( 24262325)
- Coronary artery disease or large artery stroke ( 24262325)
- Coronary heart disease ( 19198611 21378990)
- End stage renal disease x APOL1 genotype interaction ( 29885931)
- HDL cholesterol ( 25961943 20686565)
- HDL cholesterol levels ( 32203549)
- HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716)
- HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716)
- Heart failure ( 31919418)
- Ischemic stroke (large artery atherosclerosis) ( 29531354)
- LDL cholesterol ( 24097068 30275531 25961943 20686565)
- LDL cholesterol levels ( 32203549)
- LDL cholesterol levels in current drinkers ( 30698716)
- LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716)
- LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716)
- Lipid or lipoprotein levels ( 23696881)
- Lipoprotein (a) levels ( 26377243 30108283 33115273 28512139)
- Lipoprotein (a) levels in coronary artery disease (percutaneous coronary intervention) ( 31186284)
- Lipoprotein (a) levels in response to niacin in statin-treated individuals ( 30371334)
- Lipoprotein phospholipase A2 activity in cardiovascular disease ( 28753643)
- Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms ( 28512139)
- Lipoprotein-associated phospholipase A2 activity change in response to statin therapy ( 23118302)
- Low density lipoprotein cholesterol levels ( 32154731)
- Low density lipoprotein cholesterol levels (on statin treatment) ( 31969989)
- Lp (a) levels ( 21900290 19124843)
- Medication use (agents acting on the renin-angiotensin system) ( 31015401)
- Medication use (antithrombotic agents) ( 31015401)
- Medication use (beta blocking agents) ( 31015401)
- Medication use (HMG CoA reductase inhibitors) ( 31015401)
- Medication use (salicylic acid and derivatives) ( 31015401)
- Medication use (vasodilators used in cardiac diseases) ( 31015401)
- Metabolic syndrome ( 31589552)
- Metabolite levels (lipoprotein measures) ( 27005778)
- Minimum ankle–brachial index ( 31285632)
- Monocyte early outgrowth colony forming units ( 21493818)
- Myocardial infarction ( 26343387)
- Parental lifespan ( 30642433 29030599)
- Parental longevity (both parents in top 10%) ( 29227965)
- Parental longevity (combined parental age at death) ( 29227965)
- Parental longevity (combined parental attained age, Martingale residuals) ( 29227965)
- Parental longevity (father's age at death) ( 31484785 29227965)
- Parental longevity (father's attained age) ( 29227965)
- Parental longevity (mother's age at death or mother's attained age) ( 31484785)
- Parental longevity (mother's age at death) ( 29227965)
- Parental longevity (mother's attained age) ( 29227965)
- Peripheral artery disease ( 31285632)
- Plasma plasminogen levels ( 25208887)
- Plateletcrit ( 32888494)
- Protein quantitative trait loci ( 18464913)
- Response to statin therapy ( 22368281)
- Response to statins (LDL cholesterol change) ( 25350695 22331829 31969989)
- Response to statins (LDL cholesterol percent change) ( 31969989)
- Total cholesterol levels ( 28334899 30275531)
- Triglyceride levels ( 32203549 32154731)
- Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716)
- Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716)
- Triglycerides ( 30275531 25961943)
- Urinary albumin excretion ( 32277301)
|
|
Interacting Genes |
9 interacting genes:
APOH
CANX
CELA1
ELANE
FBLN5
FGB
FN1
LRP2
MMP12
|
6 interacting genes:
A2M
CSN2
LPA
PI3
SERPINA1
SERPINA3
|
Entrez ID |
4018 |
1990 |
HPRD ID |
01063 |
00553 |
Ensembl ID |
ENSG00000198670
|
ENSG00000139610
|
Uniprot IDs |
|
Q9UNI1
|
PDB IDs |
|
|
Enriched GO Terms of Interacting Partners? |
|
|
Tagcloud ? |
|
|
Tagcloud (Difference) ? |
|
|
Tagcloud (Intersection) ? |
|